Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: A two-center retrospective study

•Anti-PD-1 plus antiangiogenic therapy showed a favorable anti-NSCLC activity.•Patients with good performance status would benefit.•Patients without bone or liver metastasis would benefit.•The second-line combination therapy was more effective.•The combination therapy was well tolerated.